Literature DB >> 22684020

Regulatory role of KEAP1 and NRF2 in PPARγ expression and chemoresistance in human non-small-cell lung carcinoma cells.

Lijuan Zhan1, Hao Zhang, Qiang Zhang, Courtney G Woods, Yanyan Chen, Peng Xue, Jian Dong, Erik J Tokar, Yuanyuan Xu, Yongyong Hou, Jingqi Fu, Kathy Yarborough, Aiping Wang, Weidong Qu, Michael P Waalkes, Melvin E Andersen, Jingbo Pi.   

Abstract

The nuclear factor-E2-related factor 2 (NRF2) serves as a master regulator in cellular defense against oxidative stress and chemical detoxification. However, persistent activation of NRF2 resulting from mutations in NRF2 and/or downregulation of or mutations in its suppressor, Kelch-like ECH-associated protein 1 (KEAP1), is associated with tumorigenicity and chemoresistance of non-small-cell lung carcinomas (NSCLCs). Thus, inhibiting the NRF2-mediated adaptive antioxidant response is widely considered a promising strategy to prevent tumor growth and reverse chemoresistance in NSCLCs. Unexpectedly, stable knockdown of KEAP1 by lentiviral shRNA sensitized three independent NSCLC cell lines (A549, HTB-178, and HTB-182) to multiple chemotherapeutic agents, including arsenic trioxide (As(2)O(3)), etoposide, and doxorubicin, despite moderately increased NRF2 levels. In lung adenocarcinoma epithelial A549 cells, silencing of KEAP1 augmented the expression of peroxisome proliferator-activated receptor γ (PPARγ) and genes associated with cell differentiation, including E-cadherin and gelsolin. In addition, KEAP1-knockdown A549 cells displayed attenuated expression of the proto-oncogene cyclin D1 and markers for cancer stem cells (CSCs) and reduced nonadherent sphere formation. Moreover, deficiency of KEAP1 led to elevated induction of PPARγ in response to As(2)O(3). Pretreatment of A549 cells with PPARγ agonists activated PPARγ and augmented the cytotoxicity of As(2)O(3). A mathematical model was formulated to advance a hypothesis that differential regulation of PPARγ and detoxification enzymes by KEAP1 and NRF2 may underpin the observed landscape changes in chemosensitivity. Collectively, suppression of KEAP1 expression in human NSCLC cells resulted in sensitization to chemotherapeutic agents, which may be attributed to activation of PPARγ and subsequent alterations in cell differentiation and CSC abundance.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22684020      PMCID: PMC3418425          DOI: 10.1016/j.freeradbiomed.2012.05.041

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  53 in total

1.  Expression of peroxisome proliferator-activated receptor (PPAR)-gamma in human lung cancer.

Authors:  K Inoue; Y Kawahito; Y Tsubouchi; R Yamada; M Kohno; Y Hosokawa; D Katoh; D Bishop-Bailey; T Hla; H Sano
Journal:  Anticancer Res       Date:  2001 Jul-Aug       Impact factor: 2.480

2.  Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas.

Authors:  Anthony P Heaney; Manory Fernando; William H Yong; Shlomo Melmed
Journal:  Nat Med       Date:  2002-10-15       Impact factor: 53.440

3.  The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype.

Authors:  S Zhou; J D Schuetz; K D Bunting; A M Colapietro; J Sampath; J J Morris; I Lagutina; G C Grosveld; M Osawa; H Nakauchi; B P Sorrentino
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

4.  Activation of peroxisome proliferator-activated receptor-gamma stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells.

Authors:  Teturou Satoh; Mitsuo Toyoda; Hideki Hoshino; Tsuyoshi Monden; Masanobu Yamada; Hiroyuki Shimizu; Kaoru Miyamoto; Masatomo Mori; Masanabu Yamada; Matsumoto Mori
Journal:  Oncogene       Date:  2002-03-28       Impact factor: 9.867

5.  Peroxisome proliferator-activated receptor gamma-mediated differentiation: a mutation in colon cancer cells reveals divergent and cell type-specific mechanisms.

Authors:  Rajnish A Gupta; Pasha Sarraf; Elisabetta Mueller; Jeffrey A Brockman; Jeffery J Prusakiewicz; Charis Eng; Timothy M Willson; Raymond N DuBois
Journal:  J Biol Chem       Date:  2003-02-18       Impact factor: 5.157

6.  Transcription factor Nrf2 activation by inorganic arsenic in cultured keratinocytes: involvement of hydrogen peroxide.

Authors:  Jingbo Pi; Wei Qu; Jeffrey M Reece; Yoshito Kumagai; Michael P Waalkes
Journal:  Exp Cell Res       Date:  2003-11-01       Impact factor: 3.905

7.  Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer.

Authors:  Venkateshwar G Keshamouni; Raju C Reddy; Douglas A Arenberg; Binju Joel; Victor J Thannickal; Gregory P Kalemkerian; Theodore J Standiford
Journal:  Oncogene       Date:  2004-01-08       Impact factor: 9.867

8.  Acrolein causes transcriptional induction of phase II genes by activation of Nrf2 in human lung type II epithelial (A549) cells.

Authors:  R Tirumalai; T Rajesh Kumar; Kim Hue Mai; Shyam Biswal
Journal:  Toxicol Lett       Date:  2002-06-07       Impact factor: 4.372

9.  Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice.

Authors:  E Elstner; C Müller; K Koshizuka; E A Williamson; D Park; H Asou; P Shintaku; J W Said; D Heber; H P Koeffler
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

10.  Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor gamma in human lung carcinoma cells.

Authors:  Shouwei Han; Neil Sidell; Paul B Fisher; Jesse Roman
Journal:  Clin Cancer Res       Date:  2004-03-15       Impact factor: 12.531

View more
  16 in total

1.  Nrf2a modulates the embryonic antioxidant response to perfluorooctanesulfonic acid (PFOS) in the zebrafish, Danio rerio.

Authors:  Karilyn E Sant; Paul P Sinno; Haydee M Jacobs; Alicia R Timme-Laragy
Journal:  Aquat Toxicol       Date:  2018-02-20       Impact factor: 4.964

2.  CDK20 interacts with KEAP1 to activate NRF2 and promotes radiochemoresistance in lung cancer cells.

Authors:  Q Wang; J Ma; Y Lu; S Zhang; J Huang; J Chen; J-X Bei; K Yang; G Wu; K Huang; J Chen; S Xu
Journal:  Oncogene       Date:  2017-05-22       Impact factor: 9.867

3.  Activation of nuclear factor erythroid 2-related factor 2 coordinates dimethylarginine dimethylaminohydrolase/PPAR-γ/endothelial nitric oxide synthase pathways that enhance nitric oxide generation in human glomerular endothelial cells.

Authors:  Zaiming Luo; Shakil Aslam; William J Welch; Christopher S Wilcox
Journal:  Hypertension       Date:  2015-02-17       Impact factor: 10.190

Review 4.  The transcription factor NF-E2-related factor 2 (Nrf2): a protooncogene?

Authors:  Phillip Shelton; Anil K Jaiswal
Journal:  FASEB J       Date:  2012-10-29       Impact factor: 5.191

5.  Sodium arsenite induces spatial learning and memory impairment associated with oxidative stress and activates the Nrf2/PPARγ pathway against oxidative injury in mice hippocampus.

Authors:  Liang Xiong; Jinyu Huang; Ying Gao; Yanfang Gao; Chunmei Wu; Shengfa He; Lijun Zou; Dongmei Yang; Yuhao Han; Qiong Yuan; Zuobing Zheng; Gonghua Hu
Journal:  Toxicol Res (Camb)       Date:  2021-02-17       Impact factor: 3.524

6.  TrxR1, Gsr, and oxidative stress determine hepatocellular carcinoma malignancy.

Authors:  Michael R McLoughlin; David J Orlicky; Justin R Prigge; Pushya Krishna; Emily A Talago; Ian R Cavigli; Sofi Eriksson; Colin G Miller; Jean A Kundert; Volkan I Sayin; Rachel A Sabol; Joshua Heinemann; Luke O Brandenberger; Sonya V Iverson; Brian Bothner; Thales Papagiannakopoulos; Colin T Shearn; Elias S J Arnér; Edward E Schmidt
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-16       Impact factor: 12.779

7.  Keap1 expression has independent prognostic value in pancreatic adenocarcinomas.

Authors:  Joel Isohookana; Kirsi-Maria Haapasaari; Ylermi Soini; Peeter Karihtala
Journal:  Diagn Pathol       Date:  2015-04-16       Impact factor: 2.644

Review 8.  Role of glutathione in cancer progression and chemoresistance.

Authors:  Nicola Traverso; Roberta Ricciarelli; Mariapaola Nitti; Barbara Marengo; Anna Lisa Furfaro; Maria Adelaide Pronzato; Umberto Maria Marinari; Cinzia Domenicotti
Journal:  Oxid Med Cell Longev       Date:  2013-05-20       Impact factor: 6.543

Review 9.  The involvement of NRF2 in lung cancer.

Authors:  Alison K Bauer; Thomas Hill; Carla-Maria Alexander
Journal:  Oxid Med Cell Longev       Date:  2013-03-18       Impact factor: 6.543

Review 10.  Redox Control of Multidrug Resistance and Its Possible Modulation by Antioxidants.

Authors:  Aysegul Cort; Tomris Ozben; Luciano Saso; Chiara De Luca; Liudmila Korkina
Journal:  Oxid Med Cell Longev       Date:  2016-01-05       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.